France hospital covid-19 patient France

Stewardship / Resistance Scan for Feb 03, 2021

Reading now: 547
www.cidrap.umn.edu

CARB-X funds work on novel antibiotic for carbapenem-resistant pathogensCARB-X announced today that it is awarding up to $6.4 million to French biopharmaceutical firm Mutabilis to develop a new class of antibiotics to treat infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria.The award from CARB-X (the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) will help fund the preclinical development of EBL-1463, a potential first in-class representative of the dabocin family.

The compound is a non-beta-lactam inhibitor of penicillin-binding proteins that kills bacteria by interfering with cell wall synthesis.

Read more on cidrap.umn.edu
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA